Publications:

---

Sustained Improvement in the Management of Patients with Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocation: Where Are We Running?

Current Oncology (Toronto, Ont.)

Spitaleri, Gianluca G; Trillo Aliaga, Pamela P; Attili, Ilaria I; Del Signore, Ester E; Corvaja, Carla C; Corti, Chiara C; Crimini, Edoardo E; Passaro, Antonio A; de Marinis, Filippo F

Publication Date: 2023-05-16

Variant appearance in text: ALK: S1206C

PubMed Link: 37232842

Variant Present in the following documents:

• Main text
• curroncol-30-00384.pdf

View BVdb publication page

---

EML4-ALK biology and drug resistance in Non-Small Cell Lung Cancer: a new phase of discoveries.

Molecular Oncology

Elshatlawy, Mariam M; Sampson, Josephina J; Clarke, Katy K; Bayliss, Richard R

Publication Date: 2023-05-07

Variant appearance in text: ALK: S1206C

PubMed Link: 37149843

Variant Present in the following documents:

• Main text
• MOL2-17-950.pdf

View BVdb publication page

---

Non-Small Cell Lung Cancer Targeted Therapy: Drugs and Mechanisms of Drug Resistance.

International Journal Of Molecular Sciences

Wu, Jiajia J; Lin, Zhenghong Z

Publication Date: 2022-12-01

Variant appearance in text: ALK: S1206C

PubMed Link: 36499382

Variant Present in the following documents:

• Main text
• ijms-23-15056.pdf

View BVdb publication page

---

The Landscape of ALK-Rearranged Non-Small Cell Lung Cancer: A Comprehensive Review of Clinicopathologic, Genomic Characteristics, and Therapeutic Perspectives.

Cancers

Cognigni, Valeria V; Pecci, Federica F; Lupi, Alessio A; Pinterpe, Giada G; De Filippis, Chiara C; Felicetti, Cristiano C; Cantini, Luca L; Berardi, Rossana R

Publication Date: 2022-09-29

Variant appearance in text: ALK: S1206C

PubMed Link: 36230686

Variant Present in the following documents:

• Main text
• cancers-14-04765.pdf

View BVdb publication page

---

Molecular targeted therapy for anticancer treatment.

Experimental & Molecular Medicine

Min, Hye-Young HY; Lee, Ho-Young HY

Publication Date: 2022-10

Variant appearance in text: ALK: S1206C

PubMed Link: 36224343

Variant Present in the following documents:

• Main text
• 12276_2022_Article_864.pdf

View BVdb publication page

---

Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021.

Journal Of Hematology & Oncology

Wu, Qing Q; Qian, Wei W; Sun, Xiaoli X; Jiang, Shaojie S

Publication Date: 2022-10-08

Variant appearance in text: ALK: S1206C

PubMed Link: 36209184

Variant Present in the following documents:

• Main text
• 13045_2022_Article_1362.pdf

View BVdb publication page

---

Durable clinical response to ALK tyrosine kinase inhibitors in ALK-rearranged non-small cell lung cancer: a case report.

Translational Cancer Research

Hu, Han H; Dai, Hui H; Ding, Liren L

Publication Date: 2022-08

Variant appearance in text: ALK: S1206C

PubMed Link: 36093526

Variant Present in the following documents:

• Main text
• tcr-11-08-2967.pdf

View BVdb publication page

---

Holistic View of ALK TKI Resistance in ALK-Positive Anaplastic Large Cell Lymphoma.

Frontiers In Oncology

Wang, Yuan Y; He, Jing J; Xu, Manyu M; Xue, Qingfeng Q; Zhu, Cindy C; Liu, Juan J; Zhang, Yaping Y; Shi, Wenyu W

Publication Date: 2022

Variant appearance in text: ALK: S1206C

PubMed Link: 35211406

Variant Present in the following documents:

• Main text
• fonc-12-815654.pdf

View BVdb publication page

---

Deciphering the Mechanism of Gilteritinib Overcoming Lorlatinib Resistance to the Double Mutant I1171N/F1174I in Anaplastic Lymphoma Kinase.

Frontiers In Cell And Developmental Biology

Liang, Shuai S; Wang, Qing Q; Qi, Xuesen X; Liu, Yudi Y; Li, Guozhen G; Lu, Shaoyong S; Mou, Linkai L; Chen, Xiangyu X

Publication Date: 2021

Variant appearance in text: ALK: S1206C

PubMed Link: 35004700

Variant Present in the following documents:

• Main text
• fcell-09-808864.pdf

View BVdb publication page

---

Synthetic Heterocyclic Derivatives as Kinase Inhibitors Tested for the Treatment of Neuroblastoma.

Molecules (Basel, Switzerland)

Musumeci, Francesca F; Cianciusi, Annarita A; D'Agostino, Ilaria I; Grossi, Giancarlo G; Carbone, Anna A; Schenone, Silvia S

Publication Date: 2021-11-23

Variant appearance in text: ALK: S1206C

PubMed Link: 34885651

Variant Present in the following documents:

• Main text
• molecules-26-07069.pdf

View BVdb publication page

---

Synthetic Heterocyclic Derivatives as Kinase Inhibitors Tested for the Treatment of Neuroblastoma.

Molecules (Basel, Switzerland)

Musumeci, Francesca F; Cianciusi, Annarita A; D'Agostino, Ilaria I; Grossi, Giancarlo G; Carbone, Anna A; Schenone, Silvia S

Publication Date: 2021-11-23

Variant appearance in text: ALK: S1206C

PubMed Link: 34885651

Variant Present in the following documents:

• Main text
• molecules-26-07069.pdf

View BVdb publication page

---

Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL.

Cancers

Hare, Lucy L; Burke, G A Amos GAA; Turner, Suzanne D SD

Publication Date: 2021-11-29

Variant appearance in text: ALK: S1206C

PubMed Link: 34885113

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL.

Cancers

Hare, Lucy L; Burke, G A Amos GAA; Turner, Suzanne D SD

Publication Date: 2021-11-29

Variant appearance in text: ALK: S1206C

PubMed Link: 34885113

Variant Present in the following documents:

• Main text

View BVdb publication page

---

The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer.

Frontiers In Oncology

Pan, Yue Y; Deng, Chao C; Qiu, Zhenhua Z; Cao, Chenghui C; Wu, Fang F

Publication Date: 2021

Variant appearance in text: ALK: S1206C

PubMed Link: 34660278

Variant Present in the following documents:

• Main text
• fonc-11-713530.pdf

View BVdb publication page

---

Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis.

Frontiers In Endocrinology

Hescheler, Daniel A DA; Riemann, Burkhard B; Hartmann, Milan J M MJM; Michel, Maximilian M; Faust, Michael M; Bruns, Christiane J CJ; Alakus, Hakan H; Chiapponi, Costanza C

Publication Date: 2021

Variant appearance in text: ALK: S1206C

PubMed Link: 34630336

Variant Present in the following documents:

• Table_1.xlsx, sheet 2

View BVdb publication page

---

TPX-0131, a Potent CNS-penetrant, Next-generation Inhibitor of Wild-type ALK and ALK-resistant Mutations.

Molecular Cancer Therapeutics

Murray, Brion W BW; Zhai, Dayong D; Deng, Wei W; Zhang, Xin X; Ung, Jane J; Nguyen, Vivian V; Zhang, Han H; Barrera, Maria M; Parra, Ana A; Cowell, Jessica J; Lee, Dong J DJ; Aloysius, Herve H; Rogers, Evan E

Publication Date: 2021-09

Variant appearance in text: ALK: S1206C

PubMed Link: 34158340

Variant Present in the following documents:

• 1499.pdf

View BVdb publication page

---

An insight into lung cancer: a comprehensive review exploring ALK TKI and mechanisms of resistance.

Bosnian Journal Of Basic Medical Sciences

Patcas, Adela A; Chis, Ana Florica AF; Militaru, Claudia Florentina CF; Bordea, Ioana Roxana IR; Rajnoveanu, Ruxandra R; Coza, Ovidiu Florin OF; Hanna, Reem R; Tiberiu, Tamas T; Todea, Doina Adina DA

Publication Date: 2022-02-01

Variant appearance in text: ALK: S1206C

PubMed Link: 34082691

Variant Present in the following documents:

• Main text
• BJBMS-22-1.pdf

View BVdb publication page

---

Current Knowledge about Mechanisms of Drug Resistance against ALK Inhibitors in Non-Small Cell Lung Cancer.

Cancers

Smolle, Elisabeth E; Taucher, Valentin V; Lindenmann, Joerg J; Jost, Philipp J PJ; Pichler, Martin M

Publication Date: 2021-02-09

Variant appearance in text: ALK: S1206C

PubMed Link: 33572278

Variant Present in the following documents:

• Main text
• cancers-13-00699.pdf

View BVdb publication page

---

Resistance to anaplastic lymphoma kinase inhibitors: knowing the enemy is half the battle won.

Translational Lung Cancer Research

Tabbò, Fabrizio F; Reale, Maria Lucia ML; Bironzo, Paolo P; Scagliotti, Giorgio V GV

Publication Date: 2020-12

Variant appearance in text: ALK: S1206C

PubMed Link: 33489817

Variant Present in the following documents:

• Main text
• tlcr-09-06-2545.pdf

View BVdb publication page

---

The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer.

Pharmaceuticals (Basel, Switzerland)

Gristina, Valerio V; La Mantia, Maria M; Iacono, Federica F; Galvano, Antonio A; Russo, Antonio A; Bazan, Viviana V

Publication Date: 2020-12-18

Variant appearance in text: ALK: S1206C

PubMed Link: 33352844

Variant Present in the following documents:

• Main text
• pharmaceuticals-13-00474.pdf

View BVdb publication page

---

Optimal Care for Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: A Review on the Role and Utility of ALK Inhibitors.

Cancer Management And Research

Singh, Abhay A; Chen, Hongbin H

Publication Date: 2020

Variant appearance in text: ALK: S1206C

PubMed Link: 32821158

Variant Present in the following documents:

• Main text
• cmar-12-6615.pdf

View BVdb publication page

---

Identification of targeted therapy options for gastric adenocarcinoma by comprehensive analysis of genomic data.

Gastric Cancer : Official Journal Of The International Gastric Cancer Association And The Japanese Gastric Cancer Association

Hescheler, Daniel A DA; Plum, Patrick S PS; Zander, Thomas T; Quaas, Alexander A; Korenkov, Michael M; Gassa, Asmae A; Michel, Maximilian M; Bruns, Christiane J CJ; Alakus, Hakan H

Publication Date: 2020-07

Variant appearance in text: ALK: S1206C

PubMed Link: 32107691

Variant Present in the following documents:

• 10120_2020_1045_MOESM1_ESM.xlsx, sheet 12

View BVdb publication page

---

Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer.

Thoracic Cancer

Takahashi, Ken K; Seto, Yosuke Y; Okada, Koutaroh K; Uematsu, Shinya S; Uchibori, Ken K; Tsukahara, Mika M; Oh-Hara, Tomoko T; Fujita, Naoya N; Yanagitani, Noriko N; Nishio, Makoto M; Okubo, Kenichi K; Katayama, Ryohei R

Publication Date: 2020-03

Variant appearance in text: ALK: S1206C

PubMed Link: 31943796

Variant Present in the following documents:

• Main text
• TCA-11-581.pdf

View BVdb publication page

---

A case of primary pulmonary atypical carcinoid with EML4-ALK rearrangement.

Cancer Biology & Therapy

Liu, Na N; Wang, Jingjing J; Fu, Xiao X; Zheng, Xiaoqiang X; Gao, Huan H; Tian, Tao T; Ruan, Zhiping Z; Yao, Yu Y

Publication Date: 2020

Variant appearance in text: ALK: S1206C

PubMed Link: 31559892

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Targeting anaplastic lymphoma kinase in neuroblastoma.

Apmis : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica

Umapathy, Ganesh G; Mendoza-Garcia, Patricia P; Hallberg, Bengt B; Palmer, Ruth H RH

Publication Date: 2019-05

Variant appearance in text: ALK: S1206C

PubMed Link: 30803032

Variant Present in the following documents:

• Main text
• APM-127-288.pdf

View BVdb publication page

---

Circulating tumor cells (CTCs) for the noninvasive monitoring and personalization of non-small cell lung cancer (NSCLC) therapies.

Journal Of Thoracic Disease

Pawlikowska, Patrycja P; Faugeroux, Vincent V; Oulhen, Marianne M; Aberlenc, Agathe A; Tayoun, Tala T; Pailler, Emma E; Farace, Françoise F

Publication Date: 2019-01

Variant appearance in text: ALK: S1206C

PubMed Link: 30775027

Variant Present in the following documents:

• Main text

View BVdb publication page

---

(J)ALEX the great: a new era in the world of ALK inhibitors.

Journal Of Thoracic Disease

Brosseau, Solenn S; Gounant, Valérie V; Zalcman, Gérard G

Publication Date: 2018-07

Variant appearance in text: ALK: S1206C

PubMed Link: 30123543

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Structure and energy based quantitative missense variant effect analysis provides insights into drug resistance mechanisms of anaplastic lymphoma kinase mutations.

Scientific Reports

Li, Jianzong J; Huang, Yue Y; Wu, Miaomiao M; Wu, Chuanfang C; Li, Xin X; Bao, Jinku J

Publication Date: 2018-07-13

Variant appearance in text: ALK: S1206C

PubMed Link: 30006516

Variant Present in the following documents:

• Main text
• 41598_2018_28752_MOESM5_ESM.xlsx, sheet 1
• 41598_2018_Article_28752.pdf
• 41598_2018_28752_MOESM7_ESM.xlsx, sheet 1
• 41598_2018_28752_MOESM3_ESM.xlsx, sheet 1

View BVdb publication page

---

Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer.

Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research

McCoach, Caroline E CE; Le, Anh T AT; Gowan, Katherine K; Jones, Kenneth K; Schubert, Laura L; Doak, Andrea A; Estrada-Bernal, Adriana A; Davies, Kurtis D KD; Merrick, Daniel T DT; Bunn, Paul A PA; Purcell, W Tom WT; Dziadziuszko, Rafal R; Varella-Garcia, Marileila M; Aisner, Dara L DL; Camidge, D Ross DR; Doebele, Robert C RC

Publication Date: 2018-07-15

Variant appearance in text: ALK: S1206C

PubMed Link: 29636358

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes.

Cancers

Sharma, Geeta Geeta GG; Mota, Ines I; Mologni, Luca L; Patrucco, Enrico E; Gambacorti-Passerini, Carlo C; Chiarle, Roberto R

Publication Date: 2018-02-28

Variant appearance in text: ALK: S1206C

PubMed Link: 29495603

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Drug resistance in anaplastic lymphoma kinase-rearranged lung cancer.

Cancer Science

Katayama, Ryohei R

Publication Date: 2018-03

Variant appearance in text: ALK: S1206C

PubMed Link: 29336091

Variant Present in the following documents:

• Main text
• CAS-109-572.pdf

View BVdb publication page

---

Targeting ALK: Precision Medicine Takes on Drug Resistance.

Cancer Discovery

Lin, Jessica J JJ; Riely, Gregory J GJ; Shaw, Alice T AT

Publication Date: 2017-02

Variant appearance in text: ALK: S1206C

PubMed Link: 28122866

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Focus on Alectinib and Competitor Compounds for Second-Line Therapy in ALK-Rearranged NSCLC.

Frontiers In Medicine

Tran, Phu N PN; Klempner, Samuel J SJ

Publication Date: 2016

Variant appearance in text: ALK: S1206C

PubMed Link: 27965961

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Resisting Resistance: Targeted Therapies in Lung Cancer.

Trends In Cancer

Lin, Jessica J JJ; Shaw, Alice T AT

Publication Date: 2016-07

Variant appearance in text: ALK: S1206C

PubMed Link: 27819059

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.

Cancer Discovery

Gainor, Justin F JF; Dardaei, Leila L; Yoda, Satoshi S; Friboulet, Luc L; Leshchiner, Ignaty I; Katayama, Ryohei R; Dagogo-Jack, Ibiayi I; Gadgeel, Shirish S; Schultz, Katherine K; Singh, Manrose M; Chin, Emily E; Parks, Melissa M; Lee, Dana D; DiCecca, Richard H RH; Lockerman, Elizabeth E; Huynh, Tiffany T; Logan, Jennifer J; Ritterhouse, Lauren L LL; Le, Long P LP; Muniappan, Ashok A; Digumarthy, Subba S; Channick, Colleen C; Keyes, Colleen C; Getz, Gad G; Dias-Santagata, Dora D; Heist, Rebecca S RS; Lennerz, Jochen J; Sequist, Lecia V LV; Benes, Cyril H CH; Iafrate, A John AJ; Mino-Kenudson, Mari M; Engelman, Jeffrey A JA; Shaw, Alice T AT

Publication Date: 2016-10

Variant appearance in text: ALK: S1206C

PubMed Link: 27432227

Variant Present in the following documents:

• Main text

View BVdb publication page

---